anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a kind of Artemisia argyi Levl. et Van. var. argyi cv. Qiai quintessence oil and its preparation method and application, its preparation method comprises the following steps: takes and plucks the Folium Artemisiae Argyi of natural drying during Qichun, Hubei mid-June, loads supercritical extraction unit after pulverizing；Heating in water bath, makes supercritical extraction unit reach the temperature set, and is passed through CO 2 , the air in system is replaced clean；Pressure in regulation supercritical extraction unit, and regulate outlet valve, make CO 2 Flow reaches the stationary value of requirement, and maintenance system, at this state 50 ~ 70 min, obtains the thick product of quintessence oil；The thick product of quintessence oil extracted is added in dehydrated alcohol, places after stirring, vacuum filtration, remove the wax component of precipitation, decompression filtrate recycling ethanol, obtain the Artemisia argyi Levl. et Van. var. argyi cv. Qiai quintessence oil of dewaxing matter.Application in the Artemisia argyi Levl. et Van. var. argyi cv. Qiai quintessence oil prevention of the present invention and alleviation chronic inflammatory disease class disease, low price, notable in prevention and alleviation chronic inflammatory disease class curative effect of disease, develop its using method easily.
Group B: Plaque-disclosing tablets will be taken by patients on chair-side showing the location of the biofilm. The patients will be given plaque disclosing tablets to be used once weekly for 3 months to evaluate their oral hygiene at home. They will be given written information in the form of leaflets on importance of cooperation and compliance. Participants in this group will receive a reminder log fill, and tablets that are not used will be asked to return to the investigator by the participants to check the compliance.
The phase I portion of the study will evaluate the safety of administering bexarotene oral capsules daily at two dose levels (300 mg/m2 and 400 mg/m2) in combination with carboplatin and Taxol®. At least 6 patients will be entered onto each dose level. Doses will not be escalated over the course of treatment of an individual patient. The recommended Phase II dose is defined as the highest dose of bexarotene oral capsules (300 mg/m2 or 400 mg/m2) in combination with carboplatin and Taxol® that induces DLT in fewer than or equal to 33% of patients.

The sequential phase II portion of the study will evaluate the efficacy of bexarotene oral capsules in combination with carboplatin and weekly Taxol® in patients with advanced non-small cell lung cancer. The efficacy will be gauged according to the rate of major response where, by definition, a major response occurs if a patient achieves either complete remission (CR) or partial remission (PR). For these patients a true response rate of 20% or greater is sufficiently large to warrant further investigation. A true response rate of 10% or less indicates that the combination is less active.
The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 weeks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-week exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
Community-associated methicillin resistant Staphylococcus Aureus (CA-MRSA) infections have increased significantly over the past decade. Nearly every major region of the country has reported infections with this organism, with some areas reporting a prevalence as high as 80%. Epidemiologic evidence points to the emergence of a new strain of MRSA within the community, with unique genetic and clinical characteristics that differentiate it from traditional hospital-associated MRSA (HA-MRSA). Unlike HA-MRSA, these CA-MRSA are often susceptible in vitro to multiple antibiotic classes (other than penicillins and cephalosporins), and often cause significant, deep-seated abscesses in healthy individuals without any known risk factors for healthcare contact. Prior to awareness of this disease, many clinicians were using penicillin and cephalosporin antibiotics for empiric treatment of cutaneous abscesses, yet widespread treatment failures in the face of increasing CA-MRSA infections did NOT occur. During a one-year retrospective study in pediatric patients at our institution, we found that nearly 50% of CA-MRSA abscesses were treated with "inappropriate" antibiotics by susceptibility profiles without any significant adverse outcomes. Many clinicians are now confronted with the dilemma of whether to change empiric antibiotic therapy to other classes to which CA-MRSA would be expected to be susceptible; the most common choices including clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or vancomycin. Unfortunately, each of these antibiotics has problems of its own in terms of increased cost, poor palatability of pediatric liquid formulation, poorer side effect profile, or necessity of IV infusion, and at this time the optimal, empiric antibiotic treatment for presumed CA-MRSA skin and soft tissue infections is unclear.

The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by CA-MRSA. We hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
PURPOSE:To induce and promote antineoplastic immunity, specifically, by adsorbing inactivated vaccinia virus to tumor cell, inactivating the proliferability of the cell by physical and chemical treatment, and using the obtained tumor cell as an immunogen under the suppressed state with a suppressor T-cell. CONSTITUTION:Tumor cell adsorbed with inactivated vaccinia virus for sensitization is treated physically and chemically to inactivate its proliferation activity, and the resultant inactivated vaccinia virus-inactivated tumor cell complex is used under the suppressed state with a suppressor T-cell to induce the immunity against tumor. Concretely, the activity of the suppressor T-cell is inactivated, the production of a specific helper T-cell to vaccinia virus is induced, a specific effector cell such as B-cell, etc. is produced by the T-cell, and the antineoplastic activity is promoted. The agent is especially effective in inhibiting the metastasis of malignant tumor. It exhibits unique activity to various kinds of tumor cells.
The present invention discloses a method of preparing a solid form of acetic acid. The method at least includes the steps of combining a solid acid and a metal acetate with a solvent to form a slurry. After a predetermined period of time, a solid form of acetic acid is recovered. The present invention also includes a solid product of acetic acid produced by the above-mentioned method. There is also disclosed a formulation including the solid product of acetic acid according to the present invention. Further, there is disclosed a cleaning system including the formulation according to the present invention.
Remission of rheumatoid arthritis (RA) is an achievable goal with currently available medications, including the anti-tumor necrosis factor (anti-TNF) agents. However, it is uncertain if patients with RA in clinical remission while treated with anti-TNF agents and background disease-modifying antirheumatic drugs (DMARD) would remain in remission if anti-TNF therapy was stopped. If remission can be sustained off anti-TNF agents, then patients may be spared the potential toxicity and costs of these medications.

The Stopping Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis (STARA) study is a multicenter, randomized, double-blind, placebo-controlled noninferiority trial that will test differences in time to relapse between patients with RA in remission who discontinue anti-TNF agents and patients with RA in remission who continue anti-TNF agents. The secondary objectives of the study are: 1) to determine if discontinuation of anti-TNF agents results in a difference in progression of joint damage on radiographs; 2) to determine if discontinuation of anti-TNF agents results in a difference in physical function, and 3) to identify predictors of relapse.

Eligible subjects will have RA in remission for at least six months while taking etanercept, infliximab, or adalimumab. An eight-week run-in period prior to randomization will be used to confirm remission. Subjects will then be randomized in a 2:1 ratio to receive one of two blinded treatments: 1) matching placebo or 2) their currently used anti-TNF agent, respectively. All subjects will maintain their current background DMARD. Clinical assessments will be performed every 12 weeks. The primary outcome is 48-week relapse-free status. Secondary outcomes include change from baseline radiographic joint damage score at 48 weeks and 100 weeks, and change from baseline physical function score at 48 weeks. Subjects who relapse before week 48 will discontinue study medication and receive treatment through their rheumatologist. Blinded treated will end at week 48 and subjects will be followed for 52 additional weeks. This study will provide important new information on the best treatment approach for patients with RA in remission.
Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
The present invention relates to a temperature check system using a kiosk. More specifically, when an epidemic is prevalent, personal information of a subject is input using a kiosk installed at the entrance of a building. The subject is photographed with a general camera and an IR camera to check body temperature. When the image information, body temperature information of the subject, and subject information are matched to transmit it to a public health authority server. The public health authority server sends a test request message to the subject showing an abnormal fever pattern to guide the subject to undergo the test before symptoms appear. So, the spread of the epidemic can be prevented.
Atrial fibrillation (AF) poses a significant risk of stroke due to thrombus formation, which primarily occurs in the left atrial appendage (LAA). Medical image-based computational fluid dynamics (CFD) simulations can provide valuable insight into patient-specific hemodynamics and could potentially enhance personalized assessment of thrombus risk. However, the importance of accurately representing the left atrial (LA) wall dynamics has not been fully resolved. In this study, we compared four modeling scenarios; rigid walls, a generic wall motion based on a reference motion, a semi-generic wall motion based on patient-specific motion, and patient-specific wall motion based on medical images. We considered a LA geometry acquired from 4D computed tomography during AF, systematically performed convergence tests to assess the numerical accuracy of our solution strategy, and quantified the differences between the four approaches. The results revealed that wall motion had no discernible impact on LA cavity hemodynamics, nor on the markers that indicate thrombus formation. However, the flow patterns within the LAA deviated significantly in the rigid model, indicating that the assumption of rigid walls may lead to errors in the estimated risk factors. In contrast, the generic, semi-generic, and patient-specific cases were qualitatively similar. The results highlight the crucial role of wall motion on hemodynamics and predictors of thrombus formation, and also demonstrate the potential of using a generic motion model as a surrogate for the more complex patient-specific motion. While the present study considered a single case, the employed CFD framework is entirely open-source and designed for adaptability, allowing for integration of additional models and generic motions.
<P>PROBLEM TO BE SOLVED: To deal with treatment of metabolic syndromes since there are many metabolic syndrome patients.  <P>SOLUTION: The process for preparing an extract of Eleutherococcus spp. is provided. The extract is provided. The composition containing the extract is provided. The method for preventing or treating at least one metabolic syndrome symptom of a subject including administering the composition to a subject requiring the prevention or treatment is provided. The method for preventing or treating diseases associated with adiponectin of a subject including administering the composition to a subject requiring the prevention or treatment is provided. The method for preventing or treating diseases associated with PPARγ of a subject including administering the composition to a subject requiring the prevention or treatment is provided. The method for reducing oxidation stress of a subject including administering the composition to a subject requiring the prevention or treatment is provided. Production of an agent for preventing or treating at least one symptom of metabolic syndrome including using the extract is provided. Production of an agent for preventing or treating disease associated with adiponectin including using the extract is provided. Production of an agent for preventing or treating disease associated with PPARγ including using the extract is provided. Production of an agent for reducing oxidation stress including using the extract is provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
BACKGROUND: The lymph node ratio (LNR) is an emerging prognostic biomarker in multiple malignancies. This study aimed to explore the prognostic role of LNR in patients with non-metastatic cervical cancer undergoing radical hysterectomy.
METHODS: Data were extracted from the SEER 17 registry. Univariate and multivariate Cox analyses were performed to identify the prognostic factors associated with cancer-specific survival (CSS). A nomogram was constructed to predict the 5-year and 10-year CSS. Survival analyses stratified by the status of LNR and different adjuvant treatments were performed using the Kaplan-Meier method.
RESULTS: A total of 8128 female patients with non-metastatic cervical cancer who underwent radical hysterectomy and regional node examination (≥8) were enrolled. Of these, 1269 (15.6%) were confirmed as lymph node-positive. Cox regression analyses showed that age, race, tumor size, tumor grade, histology, and LNR were significant factors affecting CSS. A nomogram was developed for predicting the 5-year and 10-year CSS, which showed good discrimination and calibration. Patients without lymph node involvement had inferior CSS with adjuvant treatments compared to those who did not receive further treatment. In patients with LNR ≤10%, only those receiving adjuvant radiotherapy had a trend of better CSS. In patients with an LNR between 10% and 30% and more than 30%, concurrent radiochemotherapy (CCRT) proved to be the best treatment.
CONCLUSIONS: LNR is an independent prognostic factor in patients with non-metastatic cervical cancer undergoing radical hysterectomy. For patients with negative lymph nodes, no further treatment is recommended. Patients with positive lymph nodes could benefit more from CCRT.
The invention provides a box and handle integrated lozenge which structurally comprises a packaging box and a dissolve lozenge. The dissolve lozenge is located in the middle of the packaging box. The packaging box is composed of a left box cover, a right box cover and a base. The bottom of the left box cover and the bottom of the right box cover are connected with the base through a hinge. The upper portion of the left box cover and the upper portion of the right box cover are connected together through a hook. The upper portion of the outer wall of the left box cover and the upper portion of the outer wall of the right box cover are provided with snap fasteners. The dissolve lozenge is composed of a lozenge body and a core bar. The upper end of the core bar is fixed to the center of the dissolve lozenge body, and the lower end of the core bar is inserted into the middle of the base. The inner wall of the left box cover and the inner wall of the right box cover are provided with anti-sticking isolation ribs.
NEW MATERIAL:A compound expressed by the formula. USE:An antitumor agent. PREPARATION:For example, a sea squirt (Didemnum sp.) captured in a sea-area of KERAMA Islands in OKINAWA is comminuted, homogenized and then extracted with methanol. The extract is concentrated and dried up under reduced pressure, and the resultant residue is added with water and extracted with ethyl acetate. The obtained extract is concentrated and dried up under reduced pressure, and the resultant residue is dissolved in a small amount of a methanol.chloroform mixture, passed through a silica gel column, eluted with the methanol.chloroform mixture and the eluted fraction of between 80-100ml from the start is collected and concentrated to dryness under reduced pressure. The obtained residue is dispersed in chloroform and formed yellow precipitates are filtered.
This is a pilot study to compare the hemodynamic changes that occur during induction with a novel drug combination known as ketofol with that of propofol. Propofol and ketamine are widely used as induction agents and their effects on patient hemodynamics are well known. Many of these drug-induced changes are undesirable and when used alone sometimes lead to hemodynamic effects on opposite ends of the spectrum, ie. hypotension (propofol) and hypertension (ketamine). We will investigate the hemodynamic changes associated with this drug combination referred to as "ketofol" (ketamine/propofol admixture) during induction compared with propofol as the gold standard induction agent used widely in anesthetic practice. If we validate that the changes produced by the ketofol admixture are favorable, we will then test its use in a wider setting of patient populations including emergency department intubations and the trauma setting.

Background: Propofol is a non-opioid, non-barbiturate, sedative-hypnotic agent with rapid onset and short duration of action. It possesses many favorable effects such as an antiemetic effect and reliably produces sedation and amnesia (Felfernig Jour of Royal Naval Medical Service, '06; White International Anesth Clinics, '88; Willman Ann of Emer Med, '07). However, there are several undesirable side effects such as cardiovascular and respiratory depression. In addition, Propofol as a sole agent has no analgesic properties. These drug-induced side effects have led to alternative drugs being used with the hopes of a more favorable side effect profile. Ketamine is an example of one such drug. Ketamine is a phencyclidine derivative commonly classified as a dissociative sedative with fairly rapid onset and short duration of action (Felfernig Jour of Royal Naval Medical Service, '06; White International Anesth Clinics, '88; Willman Ann of Emer Med, '07). It causes little or no respiratory and cardiovascular depression and unlike propofol, has pain relieving properties. Ketamine as a single induction agent, however, is limited by emergence phenomena including postoperative dreaming and hallucinations, however these are attenuated by the administration of benzodiazepines. Also ketamine in induction doses 1-4.5 mg/kg can have some undesirable effects on hemodynamics (opposite of propofol) in certain patient populations including ischemic heart disease (IHD), and patients with increases in intracranial hypertension and intracranial pressure (ICP). Effectiveness of the two agents in combination has been recently demonstrated and this new combination could allow a novel induction agent with favorable effects on hemodynamics (Felfernig Jour of Royal Naval Medical Service, '06; Hui Jour of Amer Soc of Anesth, '95; Willman Ann of Emer Med, '07). To date, this combination known as ketofol has been used most extensively for procedural sedation in the Emergency Department but has not yet been standardized as an induction agent. We are obtaining funding for a pilot study to validate the use of ketofol as an induction agent.
The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
Cosmetic compositions or agents, the utilization thereof, and methods for the use of in temporary reshaping of keratinous fibers are provided. In an exemplary embodiment, a cosmetic composition includes from about 0.5 to about 20 wt. % wax, from about 1.0 to about 8.0 wt. % non-ionic emulsifier, from about 10 to about 25 wt. % ethanol, and from about 30 to about 80 wt. % propellant, all in relation to the overall weight of the cosmetic composition.
PURPOSE: To obtain a high-quality hepatitis A virus vaccine(HAV) having high qualities of reproducibility, by culturing a HAV, carrying out detergent harvest of the virus, nuclease treatment, concentration, extraction with an organic solvent and purification. CONSTITUTION: A HAV is cultured in a cell sheet of a stationary surface reactor of a large area, a detergent is permeated into the infected cell sheet so as to liberate the HAV from the cell culture product. Then a non-HAV specific nucleic acid is removed from the harvested HAV by nuclease treatment. Then the HAV is concentrated by membrane and dialysis filtration or by capturing by ion exchange, extracted with a solvent such as chloroform-isoamyl alcohol and is purified by ion exchange chromatography and gel filtration chromatography. A HAV having >=95% purity with respect to protein by SD polyacrylamide gel electrophoresis and silver dyeing analysis. The levels of DNA, carbohydrate, RNA and lipid are characterized in terms of vaccine.